Jim Hamilton, an employee-benefits lawyer at Bose McKinney & Evans in Indianapolis, discussed the likelihood of a Republican-controlled U.S. House of Representatives changing or even outright repealing the health care reform law, formally known as the Patient Protection and Affordable Care Act.
Without an appeal, generic drugs are now poised to wipe away most of Lilly’s $750 million in annual U.S. revenue from Gemzar.
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
St. Louis-based Ascension Health announced Friday morning that it would open a professional service center in Indianapolis, creating up to 500 jobs by 2013.
St. Louis-based Ascension Health announced Friday morning that it would open a professional service center in Indianapolis, creating up to 500 jobs by 2013.
Warsaw-based Orthopedic implant maker Zimmer Holdings Inc. reported net income of $191.1 million, or 96 cents per share. Sales fell 1 percent to $965 million from $975.6 million.
Jan Roberts pairs numbers and nurturing—further fueled by a fight with breast cancer —to power the city's fifth largest woman-owned business.
Indiana University will no longer ask employees to fill out an online health risk assessment after more than 550 people—many anonymous—attached names to an online petition that said the plan would cause “widespread anger and disillusionment.”
A new estimate has lowered the expected cost of the federal health care overhaul to Indiana’s state government to perhaps $2.6 billion over the next decade.
Eli Lilly and Co., under pressure to gain new products after setbacks this month with two diabetes drugs, may try to acquire its partner Amylin Pharmaceuticals Inc.
CEO John Lechleiter claims Eli Lilly and Co. isn’t interested in big acquisitions to bolster its flagging drug pipeline, but its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
The division purchased by Home Health Depot markets and sells home health related items via mail and online. Terms of the deal were not disclosed.
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
Eli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly version of diabetes drug Byetta, a potential billion-dollar drug.
Columbus Regional Hospital officials say a decline in its number of inpatients and an increase in outpatients have them considering whether to proceed with a planned $108 million expansion project.
The city is kicking in up to $38 million for infrastructure upgrades to support a massive expansion of the Clarian Health campus at 16th Street and Capitol Avenue.
Terms of the deal, announced on Wednesday, call for Roche to acquire all the assets associated with Medical Automation Systems Inc.’s point-of-care information technology connectivity system.
Until all consumers are required to buy health insurance, coverage restrictions are needed to keep people from gaming the system, insurers say.
Eli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.
Health insurers, including locally based WellPoint Inc. and Advantage Health Solutions, have been looking to work with health care providers to form accountable-care organizations. But they also worry that the accountable-care concept will become nothing more than a negotiating tactic by hospitals and doctors.
